{"id":31948,"date":"2026-08-26T17:25:00","date_gmt":"2026-08-26T11:55:00","guid":{"rendered":"https:\/\/www.medicalbillersandcoders.com\/blog\/?p=31948"},"modified":"2026-08-26T17:25:00","modified_gmt":"2026-08-26T11:55:00","slug":"graft-application-billing-ctp-rule-change","status":"publish","type":"post","link":"https:\/\/www.medicalbillersandcoders.com\/blog\/graft-application-billing-ctp-rule-change\/","title":{"rendered":"Is Graft Application Billing Keeping Up With the CTP Rule Change?"},"content":{"rendered":"

Graft application billing has not kept pace with the CTP rule change for most wound care groups, and the gap shows up as underpayment on every claim still coded and documented the old way. CMS restructured how cellular and tissue-based products (CTPs) are paid under the CY 2026 Physician Fee Schedule Final Rule, moving most skin substitutes from a per-product, average-sales-price payment to a single national supply rate bundled into the application procedure.<\/p>\r\n

Practices that haven’t updated coding, documentation, and payer-verification workflows to match are either losing reimbursement they’re entitled to or exposing themselves to audit risk on claims built around a payment model that no longer exists.<\/p>\r\n

This isn’t a minor coding tweak. It’s a structural change reshaping margins at wound care centers, podiatry groups, and multi-site dermatology practices that rely on cellular and tissue-based products for diabetic foot ulcers and venous leg ulcers.<\/p>\r\n

What Actually Changed Under the CTP Rule<\/h2>\r\n

Before this rule, most skin substitutes were classified as biologicals and paid under the average sales price (ASP) methodology described in Section 1847A of the Social Security Act. Each product carried its own HCPCS code and payment limit, with rates ranging from roughly $200 to well over $3,000 per square centimeter depending on the product.<\/p>\r\n

Under the finalized CY 2026 rule, CMS reclassifies most skin substitutes as incident-to supplies, the same payment category as surgical sponges or sutures, rather than separately payable biologicals. That means the product cost is bundled into the application procedure instead of billed and reimbursed on its own.<\/p>\r\n

CMS set a single national payment rate of approximately $127.14 per square centimeter for the non-facility setting, replacing the wide product-specific range that previously existed. According to CMS’s own claims data, Part B spending on these products grew from $252 million in 2019 to more than $10 billion in 2024, a nearly 40-fold increase the agency cited as the reason for the overhaul.<\/p>\r\n

For any practice still billing graft application the way it did last year, that’s the disconnect. The application procedure code hasn’t changed much. The product-specific reimbursement it used to carry has.<\/p>\r\n

Why Graft Application Billing Is Under Pressure Right Now<\/h2>\r\n

Three things are colliding at once, and each one independently pressures margin.<\/p>\r\n

First, the payment mechanism itself changed from ASP-based, product-specific billing to a bundled supply rate. Any workflow still built around submitting separate HCPCS codes expecting product-level reimbursement is misaligned with how the claim will actually adjudicate.<\/p>\r\n

Second, coverage didn’t tighten the way most practices expected, and that’s created its own problem. CMS finalized standardized Local Coverage Determinations for diabetic foot ulcers and venous leg ulcers across all seven MACs, then withdrew them days before their effective date. There’s no uniform national coverage standard today.<\/p>\r\n

Coverage instead reverts to whatever local policy already existed, active in a handful of jurisdictions like Novitas, CGS, and First Coast, and governed by general medical necessity rules elsewhere. Some distributors have told practices that “nothing changed” because of the withdrawal. That’s misleading; the payment restructuring took effect anyway.<\/p>\r\n

Third, CMS categorized products by FDA regulatory pathway for payment purposes even without the LCD standardization, meaning two grafts billed identically a year ago may now sit in different payment groupings. Practices that haven’t remapped their formulary are billing blind on the payment side, regardless of what’s happening with coverage.<\/p>\r\n

None of this is theoretical. Practices we’ve reviewed post-transition are seeing claims paid at rates that don’t match what was billed, denials tied to jurisdiction-specific documentation requirements nobody flagged internally, and confusion over which application codes still pair correctly with which product categories.<\/p>\r\n

Old Model vs. New Model: What Changed in CTP Payment<\/h2>\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n
Element<\/strong><\/td>\r\nPre-2026 Model<\/strong><\/td>\r\nCurrent CTP Rule Model<\/strong><\/td>\r\n<\/tr>\r\n<\/thead>\r\n
Payment classification<\/td>\r\nBiological, paid separately<\/td>\r\nIncident-to supply, bundled with procedure<\/td>\r\n<\/tr>\r\n
Payment methodology<\/td>\r\nAverage Sales Price (ASP), product-specific<\/td>\r\nSingle national rate, approximately $127.14\/cm\u00b2<\/td>\r\n<\/tr>\r\n
Payment range<\/td>\r\n~$200 to $3,000+ per cm\u00b2, varied by product<\/td>\r\nFlat rate regardless of product tier<\/td>\r\n<\/tr>\r\n
Coverage basis<\/td>\r\nVariable by MAC, less standardized<\/td>\r\nStill variable by MAC; standardized DFU\/VLU LCDs were withdrawn before taking effect<\/td>\r\n<\/tr>\r\n
Product eligibility<\/td>\r\nBroad product list accepted<\/td>\r\nPayment-side FDA categories apply; coverage eligibility still set locally, jurisdiction by jurisdiction<\/td>\r\n<\/tr>\r\n
Billing structure<\/td>\r\nSeparate HCPCS code per product<\/td>\r\nApplication code carries bundled supply cost<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n

The Documentation Gaps That Are Actually Costing You Money<\/h2>\r\n

The rule change didn’t just move a decimal point. It shifted where the financial risk sits, and most of that risk now lives in the gap between payment policy and coverage policy.<\/p>\r\n

Because the standardized LCDs never took effect, medical necessity requirements still vary by jurisdiction: documentation that clears review under Novitas may not match what CGS, or a MAC with no active local policy, expects under general reasonable-and-necessary standards.<\/p>\r\n

A claim that would have cleared review a year ago can now be flagged for reasons that have nothing to do with the payment change and everything to do with which MAC is reviewing it.<\/p>\r\n

This is also where OIG scrutiny concentrates. Skin substitute billing<\/a> has already drawn attention in the OIG Work Plan given the spending growth CMS cited, and CMS has separately layered its WISeR prior-authorization pilot onto the same product category in select states. Practices treating the LCD withdrawal as “no change needed” are missing that the payment rules moved regardless.<\/p>\r\n

Getting graft application billing right now means three things happening in sync: coding aligned to the bundled supply structure, documentation built around whatever local coverage standard actually applies in each billing jurisdiction, and formulary decisions reviewed against the FDA-based product categories CMS is now using to determine payment.<\/p>\r\n

Building a Billing Workflow That Matches the Current CTP Rule<\/h2>\r\n

A graft application billing workflow that’s actually current looks different from one built two years ago. It includes real-time verification of which local coverage policy, if any, applies in a given MAC jurisdiction, coding that reflects the bundled payment structure rather than legacy product-level billing, and documentation built around whatever medical necessity standard is currently in force there, not the standardized criteria that were withdrawn.<\/p>\r\n

It also requires someone tracking policy at the source. CMS has already issued a technical correction adjusting the initial payment rate, a reminder that this policy area is still being refined and that teams relying on secondhand summaries can fall out of date quickly.<\/p>\r\n

This is precisely the kind of shift that separates generalist RCM services from teams built for high-complexity specialties. Wound care billing services<\/a> require ongoing familiarity with LCD language, HCPCS categorization, and payer-specific interpretation, not a one-time coding update. Multi-site groups that treat this as a standing compliance function, not a project that finished when the rule took effect, are the ones protecting margin through the transition.<\/p>\r\n

If your team hasn’t audited claims against the current rule, that’s the place to start. Most in-house teams and generic medical billing services weren’t built to track jurisdiction-level changes at this pace. A short structural review, benchmarked against comparable facility sizes, typically surfaces both the underpayment and the audit exposure sitting in a single billing cycle.<\/p>\r\n

Comparing your current cost structure against a specialized medical billing and coding services partner is worth doing before your next reimbursement cycle, not after a denial pattern forces the question. You can review current specialty billing service rates<\/a> to see where a dedicated wound care revenue cycle management approach stacks up against what you’re running internally.<\/p>\r\n

Summary<\/h2>\r\n

The CTP rule change replaced product-specific, ASP-based payment for most skin substitutes with a single bundled supply rate near $127.14 per square centimeter, effective under the CY 2026 Medicare Physician Fee Schedule Final Rule. The standardized coverage rules meant to accompany that shift were withdrawn by CMS days before taking effect, so coverage still runs on a jurisdiction-by-jurisdiction basis while the payment change moved forward regardless.<\/p>\r\n

Practices still billing graft application under old coding and documentation habits, or that assumed the LCD withdrawal meant nothing changed, face both underpayment and audit exposure. Closing that gap requires coding aligned to the bundled model, documentation matched to the actual local coverage standard in force, and ongoing formulary review against FDA-based product categories, not a one-time update.<\/p>\r\n

Getting graft application billing wrong under this rule doesn’t just cost reimbursement, it invites the kind of scrutiny CMS built this policy to create. If your coding, documentation, or product formulary hasn’t been reviewed since the rule took effect, MBC’s wound care billing team can run a focused claims audit against the current CTP framework before your next billing cycle closes.<\/p>\r\n

Phone: 888-357-3226<\/strong><\/a> | Email: info@medicalbillersandcoders.com<\/strong><\/a><\/p>\r\n

FAQs: Graft Application Billing<\/h2>\r\n\r\n
\r\n
1. What is the CTP rule change in Medicare billing?<\/strong><\/strong>\r\n

It’s the CY 2026 Medicare Physician Fee Schedule policy that reclassifies most skin substitutes (cellular and tissue-based products) from separately payable biologicals to bundled incident-to supplies, paid at a flat national rate instead of product-specific pricing.<\/p>\r\n<\/div>\r\n

2. How does the CTP rule change affect graft application billing?<\/strong><\/strong>\r\n

The application procedure code now carries the bundled product cost instead of pairing with a separate, product-specific HCPCS payment, so claims coded the old way often reimburse incorrectly or draw documentation-based denials.<\/p>\r\n<\/div>\r\n

3. What is the new payment rate for skin substitutes under the 2026 rule?<\/strong><\/strong>\r\n

CMS finalized a single national rate near $127.14 per square centimeter for the non-facility setting, replacing a prior range that varied by product from roughly $200 to over $3,000 per square centimeter.<\/p>\r\n<\/div>\r\n

4. Are all skin substitute products still covered under Medicare?<\/strong><\/strong>\r\n

Coverage still depends on your MAC jurisdiction. CMS withdrew the standardized national LCDs for diabetic foot ulcers and venous leg ulcers just before their effective date, so a few jurisdictions have active local policies while others rely on general medical necessity rules, not the uniform product list that was originally planned.<\/p>\r\n<\/div>\r\n

5. Why should wound care practices audit their billing after this rule change?<\/strong><\/strong>\r\n

The payment restructuring took effect even though the coverage LCDs didn’t, and that mismatch is where denials and audit exposure are showing up, especially for practices that assumed the LCD withdrawal meant no action was needed.<\/p>\r\n

Sources:<\/strong><\/p>\r\n